Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Exicure’s 3-dimensional, spherical nucleic acid (SNATM) architecture seeks to unlock the potential of nucleic acid therapeutics in multiple organs. Exicure’s lead programs address diseases from inflammatory disorders to oncology.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapy: safe and effective delivery to cells and tissues. SNA constructs exhibit unparalleled transfection efficiency across a wide range of cell and tissue types, including the skin.

SNA technology originated in the laboratory of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure’s portfolio includes more than 135 patent applications pending and more than 60 patents granted or issued.

Discover how is Exicure doing today.